Holen Sie sich die Stockscreener-App
186.76
2.32%
-6.09
Schlusskurs vom Vortag:
$192.85
Offen:
$191.09
24-Stunden-Volumen:
53,269
Relative Volume:
0.27
Marktkapitalisierung:
$7.51B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-77.61M
KGV:
-81.27
EPS:
-2.2979
Netto-Cashflow:
-
1W Leistung:
+17.26%
1M Leistung:
+15.54%
6M Leistung:
+5.17%
1J Leistung:
+186.82%
1-Tages-Spanne:
$185.00
$191.30
1-Wochen-Bereich:
$159.86
$198.58
52-Wochen-Spanne:
$64.80
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare BLTE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
186.51 | 7.77B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-26 | Eingeleitet | BofA Securities | Buy |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-02 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Eingeleitet | Mizuho | Neutral |
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Zacks Investment Research
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com UK
Mizuho raises Belite Bio stock price target on Japan drug filing - Investing.com
Belite Bio at Wells Fargo conference: nda review lifts stakes By Investing.com - Investing.com Canada
Belite Bio files Japan NDA for Stargardt disease drug - grafa.com
Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease - TipRanks
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt... - markets.businessinsider.com
Belite Bio submits drug application in Japan for Stargardt disease By Investing.com - Investing.com Canada
Belite Bio (NASDAQ: BLTE) seeks Japan OK for Stargardt pill that could be a first - Stock Titan
Canaccord initiates Belite Bio stock with buy on Stargardt therapy By Investing.com - Investing.com South Africa
Belite Bio Pops As Wall Street Backs Stargardt Bet - TipRanks
Canaccord initiates Belite Bio stock with buy on Stargardt therapy - Investing.com
Belite Bio Surges As Tinlarebant Nears FDA Decision - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans - Investing.com
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - Yahoo Finance
Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Barchart.com
Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com
Trading Systems Reacting to (BLTE) Volatility - Stock Traders Daily
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - The Manila Times
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media
Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media
Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com
Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada
Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Canada
Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares - Investing.com
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... By GuruFocus - Investing.com Canada
Belite Bio Q2 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips - Investing.com Canada
Belite Bio Q2 Earnings Call Highlights - Yahoo Finance
Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out - TipRanks
Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss - Stock Titan
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times
BLTE (NASDAQ: BLTE) files Form 144 for 93,800 ADS sale - Stock Titan
Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating - TipRanks
Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook - Investing.com
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA - TradingView
HC Wainwright Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
FDA grants priority review for Belite Bio’s Stargardt treatment By Investing.com - Investing.com Australia
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Belite Bio Inc Adr-Aktie (BLTE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lin Yu-Hsin | Chief Executive Officer |
Aug 12 '26 |
Sale |
180.35 |
365 |
65,827 |
170,569 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):